Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2019-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2019-04-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the departure of a board member, David P. Southwell, from the company's Board of Directors and the related consulting agreement. This matches the description of announcements about changes in the company's board or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and contains detailed information about the management change, not just an announcement of a report, so it is not an RPA or RNS filing. Confidence is high due to clear and explicit content about board departure and management changes.
2019-04-18 English
Regulatory Filings 2019
Regulatory Filings
2019-04-01 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-29 English
FORM 8-K/A
Board/Management Information Classification · 100% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. The content specifically relates to the election of a director and the appointment of that director to a board committee. This is a clear announcement of changes in the company's board of directors. The document is short (3140 characters) and focuses on management/board changes rather than financial results or other report types. Therefore, it fits the category of Board/Management Information (MANG).
2019-03-29 English
FORM 3 SUBMISSION
Director's Dealing
2019-03-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.